(Hypertension. 2001;38:159.)
© 2001 American Heart Association, Inc.
Scientific Contributions |
From Pharmacologie et Physicochimie des Interactions Cellulaires et Moléculaires, CNRS UMR 7034, Faculté de Pharmacie, Illkirch, France.
Correspondence to Dr Ramaroson Andriantsitohaina, Pharmacologie et Physicochimie des Interactions Cellulaires et Moléculaires, CNRS UMR 7034, 67 route du Rhin, Faculté de Pharmacie, 67401 Illkirch, France. E-mail nain{at}pharma.u-strasbg.fr
| Abstract |
|---|
|
|
|---|
Key Words: endothelium arteries nitric oxide cyclooxygenase
| Introduction |
|---|
|
|
|---|
The aim of the present study was to determine the effects of short-term oral administration of RWPCs on hemodynamic parameters, on vascular reactivity, and on the induction of gene expression in the vascular wall in normotensive rats.
| Methods |
|---|
|
|
|---|
Systolic blood pressure (SBP) and heart rate were measured daily by use of the pneumatic tail-cuff method (NarcoBio Systems).
HPLC-Electrochemical Analysis of Reduced Glutathione and Oxidized Glutathione
Rats were anesthetized with pentobarbital sodium (50 mg/kg body weight IP), and blood was collected from the aorta. All samples were analyzed on a CoulArray high-performance liquid chromatography (HPLC) instrument equipped with 8 electrochemical cells arranged in line and set to increasing specified potentials between 350 and 1000 mV (ESA Inc). The analytical column was a C-18 reverse-phase column equipped with a precolumn C-18 cartridge assembly. Isocratic elution was performed by mobile-phase 10 mmol/L sodium dihydrogen phosphate containing 1 mmol/L of the ion-pairing reagent 1-octanesulfonic acid and 3% (vol/vol) acetonitrile adjusted to pH 3.0. Sample (20 µL) was applied to the HPLC. Peak identification was performed from the retention time and the reactivity of 3 electrodes with different voltages and was quantified by comparison with authentic standards. Quantification was performed by comparing the peak area with that of the standards.
Ex Vivo Vascular Reactivity
Studies of vascular reactivity were performed 24 hours after the last dose of the 7-day treatment of rats with either glucose, Provinol, or RWPC1.
Rats were killed by cervical dislocation and then exsanguinated by carotid artery transection. The thoracic aorta was removed and mounted as previously described in a physiological salt solution.12
Endothelium-dependent relaxation was studied in thoracic aortas with functional endothelium and precontracted to 80% of the maximal response obtained with norepinephrine (0.3 µmol/L). Vasodilator agents, such as acetylcholine, the inhibitor of sarcoplasmic reticulum Ca2+-ATPase, thapsigargin, and the Ca2+ ionophore, ionomycin, were applied in cumulative fashion. In some experiments, the involvement of O2- in the relaxation to acetylcholine was studied by use of O2- scavengers, manganese (III) tetrakis-(1-methyl-4-pyridyl)porphyrin pentachloride (MnTMPyP, 100 µmol/L), or a combination of superoxide dismutase (SOD, 100 IU) plus catalase (1000 IU). Also, in some experiments, the involvement of NO was investigated by exposing the aorta with functional endothelium to the NO synthase inhibitor NG-nitro-L-arginine (L-NA, 100 µmol/L).
Concentration-response curves to norepinephrine were constructed in a cumulative manner in aortas with or without functional endothelium. To characterize the involvement of NO and cyclooxygenase (COX) products, some arteries were exposed to the NO synthase inhibitor NG-nitro-L-arginine methyl ester (L-NAME, 300 µmol/L) and the COX inhibitor indomethacin (10 µmol/L).
All inhibitors were present 30 minutes before vasoactive agonist except for O2- scavengers, which were added 15 minutes before agonist application.
TXB2 Production
The production of thromboxane B2 (TXB2) was determined in 1 mL physiological salt solution collected from aortic rings with endothelium in the absence or presence of norepinephrine added for 10 minutes. TXB2 was measured by enzyme-immunoassay system (Research & Development Systems). TXB2 production was expressed as picograms per microgram protein.
Immunoblotting With Anti-iNOS and AntiInducible COX-2 Antibodies
Aortas were homogenized, and
100 µg of total protein from the supernatant fraction was loaded onto 7% and 10% SDS-PAGE to separate inducible NO synthase (iNOS) and COX-2 proteins, respectively. After electrophoresis, proteins were transferred onto the nitrocellulose membrane. Immunostaining of iNOS and COX-2 was achieved by use of specific monoclonal mouse anti-iNOS and antiCOX-2 antibodies (Transduction Laboratories) and reacted with peroxidase-conjugated antimouse antibody. The blots were detected by using an enhanced chemiluminescence assay (ECL, Amersham).
Expression of Results and Statistical Analysis
The SBP of each animal is expressed in millimeters of mercury, and the heart rate is in beats per minute. Tension is expressed as grams per milligram of dry tissue, and relaxations are expressed as a percentage of the level of precontraction. The level of precontraction was not significantly different between control and RWPC-treated rats. All results are expressed as mean±SEM for the number of experiments or the number of rats. Sensitivities to agonists are expressed as pD2 values, where pD2=-log EC50. Students unpaired t test or ANOVA was used for statistical analysis.
Drugs
The Provinol dry powder from red wine was provided by D. Ageron (Société Française de Distillerie, Vallont Pont dArc, France), and the RWPC1 (Cabernet Sauvignon grape variety) was from Dr M. Moutounet (Institut National de la Recherche Agronomique, Montpellier, France). RWPC1 and Provinol polyphenol contents have been already described12 as RWPC1 and RWPC2, respectively. All the chemicals were purchased from Sigma Chemical Co, except for MnTMPyP (Alexis Corp).
| Results |
|---|
|
|
|---|
|
In contrast, the heart rates of the rats receiving the vehicle, Provinol, or RWPC1 were not significantly different during the treatment both within the group and between the groups (not shown). Both the reduced and oxidized forms of blood glutathione were not significantly different between control and RWPC1-treated rats (Figure 2).
|
Vasoreactivity, Western Blot Analysis, and TXB2 Production of Thoracic Aorta
Acetylcholine produced concentration-dependent relaxation in aortas from either control or Provinol-treated rats (Figure 3A). Acetylcholine failed to produce relaxation in aortas without functional endothelium or aortas with functional endothelium in the presence of the NO synthase inhibitor L-NA (100 µmol/L) from both control and Provinol-treated rats. Acetylcholine-induced relaxation was significantly potentiated in aortas taken from either Provinol-treated (P<0.05) or RWPC1-treated (P<0.05, not shown) rats compared with the response obtained in aortas from control rats. The response to acetylcholine obtained in aortic rings taken from Provinol-treated rats was significantly reduced in the presence of SOD (100 IU) plus catalase (1000 IU) (P<0.05, Figure 3A), such that the response to acetylcholine was not significantly different from that of aortas taken from control rats. Also, the response to acetylcholine was significantly reduced in the presence of MnTMPyP (100 µmol/L, P<0.05) in aortic rings from RWPC1-treated rats (not shown). Neither SOD plus catalase nor MnTMPyP significantly reduced the acetylcholine-induced relaxation in aortas taken from control rats (not shown).
|
The inhibitor of sarcoplasmic reticulum Ca2+-ATPase, thapsigargin, and the Ca2+ ionophore, ionomycin, produced concentration-dependent relaxations of aortas with intact endothelium that were not significantly different in control or Provinol-treated rats (Figure 3B and 3C).
Norepinephrine produced concentration-dependent contractions of aortas with or without functional endothelium from both control and Provinol-treated rats (Figure 4). In the presence of functional endothelium, the concentration-effect curves to norepinephrine were not significantly different in aortas taken from either control rats or rats treated with Provinol. In the absence of functional endothelium, the contractile response to norepinephrine was significantly reduced in vessels taken from Provinol-treated rats compared with vessels taken from control rats (P<0.05, Figure 4B). The maximal response to norepinephrine was significantly reduced (ie, from 3.67±0.12 to 2.67±0.43 g/mg of dry tissue; P<0.05) without any alteration of the pD2 values (ie, 8.42±0.07 and 8.32±0.36) in aortas taken from control and Provinol-treated rats, respectively. However, in endothelium-denuded aortic rings taken from Provinol-treated rats, blockade of NO synthesis with the NO synthase inhibitor L-NAME (300 µmol/L) restored the contractile response to norepinephrine toward that of aortic rings taken from control rats (Figure 5A). Furthermore, Western blot analysis of inducible NO synthase showed that although there was a weak expression of the 140-kDa form of iNOS in aortas from control rats, the expression of this isoform was markedly enhanced in aortas removed from Provinol-treated rats (Figure 5B). The iNOS expression was 2- to 3-fold higher in aortas from Provinol-treated rats compared with aortas from control rats.
|
|
Finally, in aortic rings with functional endothelium, the COX inhibitor indomethacin (10 µmol/L) did not significantly alter the contractile response to norepinephrine in the control group (not shown), but it markedly reduced the norepinephrine-induced contraction in vessels taken from Provinol-treated rats (Figure 6A, P<0.05). The maximal response to norepinephrine was significantly reduced from 3.09±0.27 to 1.66±0.20 g/mg of dry tissue (P<0.01) without any significant change in pD2 values (ie, 7.54±0.34 and 7.40±0.12) in aortas taken from control and Provinol-treated rats, respectively. Furthermore, there was a marked stimulation of TXB2 production by norepinephrine in aortic rings from Provinol-treated but not from control rats (Figure 6B). In the absence of norepinephrine, TXB2 production was not significantly different in aortas taken from the 2 groups. Moreover, aortas from Provinol-treated rats but not aortas from control rats displayed a marked expression (3-fold increase compared with control) of the 70-kDa isoform of COX-2 (Figure 6C).
|
| Discussion |
|---|
|
|
|---|
In previous studies, we reported that RWPCs from both Provinol and RWPC1 were able to produce ex vivo endothelium-dependent relaxation in rat aortic rings as a result of enhanced NO synthesis.11,12 The present study provides evidence that in vivo administration of these 2 sources of RWPCs induced in the rat a progressive decrease in blood pressure without any alteration in heart rate. The 2 preparations of RWPCs have similar contents of polyphenols but contain a large number of compounds, including phenolic acids, flavonoids, anthocyanins, and tannins. The molecular identity of the compounds responsible for the in vivo effect described in the present study has not been assessed. However, it is clear that daily feeding of rats for 1 week with 20 mg/kg RWPC is adequate to produce a sufficient circulating concentration of compounds to induce cardiovascular effects. In our previous study, the compounds from RWPCs that mediated the ex vivo endothelial NOinduced relaxation of rat aortic rings included oligomeric-condensed tannins and anthocyanins but not polymeric-condensed tannins.15 Similar polyphenols might be implicated in the in vivo effect of RWPCs and, hence, might act on the endothelium in vivo. In the present study, RWPCs decreased blood pressure in normotensive rats. It should be noted that Provinol was also able to prevent the increase in blood pressure in NO-deficient hypertensive rats (O. Pechanova, I. Bernatova, R. Andriantsitohaina, unpublished data, 2001).
The mechanism involved in the decrease in blood pressure produced by in vivo treatment with RWPCs is unknown. Very recently, it has been reported that the antithrombotic properties of red wine in vivo involve NO, inasmuch as these effects are prevented by the NO synthase inhibitor L-NAME.7 However, in the latter study, the origin of the NO production has not been established. In the present study, it can be hypothesized that NO, probably from the endothelium, might account for the decrease in blood pressure because RWPCs are able to stimulate its release in both in vitro and ex vivo experiments.7 Very recently, it has been reported that short-term ingestion of red grape juice (whose constituents include anthocyanins and tannins) improves flow-mediated endothelium-dependent vasodilatation in patients with coronary artery diseases despite the use of antioxidant vitamins.5 These authors advanced the hypothesis that the mechanisms involved NO production.
With regard to endothelium-dependent vasodilatation, it was found that acetylcholine-induced relaxation was increased in aortas taken from either Provinol- or RWPC1-treated rats. The activity of the NO pathway is probably increased in this phenomenon, inasmuch as the acetylcholine-induced relaxation in the aorta from either group was completely prevented by the NO synthase inhibitor L-NA. This could result either from augmented NO generation or from reduced NO breakdown by O2-. The latter hypothesis is unlikely because relaxation produced by 3-morpholino-sydnonimine, which spontaneously releases NO and O2-, was not significantly different in aortas taken from control and RWPC-treated rats (not shown). Thus, the increased acetylcholine-induced relaxation is probably due to enhanced NO generation. The results also show that although the relaxing effect of acetylcholine was increased, the relaxation to the sarcoplasmic reticulum Ca2+-ATPase inhibitor, thapsigargin, or to the Ca2+ ionophore, ionomycin, was not modified by RWPC treatment. It is well established that an increase in cytosolic Ca2+ ([Ca2+]i) within the endothelial cell is the principal intracellular step for the activation of NO synthase. In contrast to thapsigargin and ionomycin, which increase [Ca2+]i by direct action on Ca2+ handling, acetylcholine acts via second messengers. Therefore, it can be hypothesized that RWPC treatment improves endothelium-dependent vasodilatation by amplifying the pathway leading to second-messenger production, such as the activity of phospholipase C. On the other hand, it is interesting to note that the potentiating effect of RWPCs on acetylcholine-induced relaxation is attenuated in the presence of O2- scavengers MnTMPyP or SOD plus catalase. These results suggest that O2- production is involved in the effect of RWPC treatment. Glutathione is the most abundant antioxidant in the cell, in which it is formed predominantly in 2 redox forms: reduced glutathione and oxidized glutathione. It plays a central role in cellular defense against oxidative stress. Blood glutathione levels may reflect glutathione status in other less accessible tissues. Plasma measurement of both reduced glutathione and oxidized glutathione has been considered essential as an index of several physiological and pathophysiological situations16 and provides a sensitive index of whole-body oxidative stress.17 In the present study, no increase in the levels of GSSG was observed in the plasma from RWPC-treated rats. Thus, the involvement of O2- scavengersensitive mechanisms in the improved relaxation to acetylcholine in vessels from RWPC-treated rats was not the consequence of an enhanced production of reactive oxygen species in the circulation. This observation is surprising, because O2- is known to be implicated in the breakdown of NO.18 However, these results are in accordance with the in vitro effect of RWPCs in cultured bovine endothelial cells, in which O2- production is implicated in the RWPC-induced rise in [Ca2+]i.19 This observation is also consistent with data reported in the literature, showing that O2- induces an increase of [Ca2+]i in human umbilical vein and aortic endothelial cells.20,21 In addition, the induction of O2- production by high glucose concentrations enhances agonist-stimulated Ca2+/NO signaling in porcine aortic endothelial cells.22 Therefore, the results from the present study suggest that increase of O2- plays a role in the enhanced acetylcholine-induced vasodilatation that is due to endothelial NO after treatment of the rat with RWPCs. These results may explain in part the cardioprotective effect of moderate red wine consumption.
Turning now to the effect of RWPC treatment on vascular reactivity in response to a vasoconstrictor agonist, we note that the contractions to norepinephrine were unchanged by RWPCs in aortas with functional endothelium. In endothelium-denuded aortic rings from RWPC-treated rats, the norepinephrine-induced contraction was decreased; this hyporeactivity was prevented by the NO synthase inhibitor L-NAME and was associated with an increased expression of iNOS in the vessel. Taken together, these data are consistent with the hypothesis that RWPC treatment elicits extraendothelial production of NO from iNOS, which leads to vascular hyporeactivity toward norepinephrine. Meanwhile, the hyporeactivity to norepinephrine did not occur in RWPC-treated aortas that contained a functional endothelium; in these vessels, the COX inhibitor indomethacin decreased the contraction to norepinephrine. The inhibitory effect of indomethacin may be explained by the observation that there was an increase in TXB2 production, the stable product of TXA2, in aortic rings stimulated by norepinephrine from RWPC-treated rats. Moreover, aortas from RWPC-treated rats but not those from control rats displayed a marked expression of the COX-2 isoform. Taken together, these results suggest that RWPC treatment is associated with increased participation in vascular regulation of endothelial vasoconstrictor products from COX, probably TXA2, arising from the induction of COX-2. Thus, the present study highlights the induction of gene expression (ie, of iNOS and COX-2) by RWPCs, which allows maintenance of norepinephrine-induced contraction. This implies that there is a subtle balance between extraendothelial NO production, inducing vascular hyporeactivity, and increased endothelial release of vasoconstrictor products from COX (ie, TXA2) in aortas taken from RWPC-treated rats.
In conclusion, the present study provides evidence that short-term oral administration of RWPC produces a decrease in blood pressure in normotensive rats. This hemodynamic effect of RWPC was associated with an augmentation of endothelium-dependent relaxation and a modest induction of gene expression of iNOS and COX-2 within the arterial wall, which together maintain unchanged agonist-induced contractility. These cardiovascular effects of RWPC may contribute to the beneficial effects of moderate red wine consumption against coronary artery disease.
| Acknowledgments |
|---|
Received November 13, 2000; first decision January 10, 2001; accepted February 6, 2001.
| References |
|---|
|
|
|---|
2.
Feng AN, Chen YL, Chen YT, Ding YZ, Lin SJ. Red wine inhibits monocyte chemotactic protein-1 expression and modestly reduces neointimal hyperplasia after balloon injury in cholesterol-fed rabbits. Circulation. 1999; 100: 22542259.
3. Xia J, Allenbrand B, Sun GY. Dietary supplementation of grape polyphenols and chronic ethanol administration on LDL oxidation and platelet function in rats. Life Sci. 1998; 63: 383390.[Medline] [Order article via Infotrieve]
4. Nigdikar SV, Williams NR, Griffin BA, Howard AN. Consumption of red wine polyphenols reduces the susceptibility of low-density lipoproteins to oxidation in vivo. Am J Clin Nutr. 1998; 68: 258265.[Abstract]
5.
Stein JH, Keevil JG, Wiebe DA, Aeschlimann S, Folts JD. Purple grape juice improves endothelial function and reduces the susceptibility of LDL cholesterol to oxidation in patients with coronary artery disease. Circulation. 1999; 100: 10501055.
6.
Demrow HS, Slane PR, Folts JD. Administration of wine and grape juice inhibits in vivo platelet activity and thrombosis in stenosed canine coronary arteries. Circulation. 1995; 91: 11821188.
7. Wollny T, Aiello L, Di Tommaso D, Bellavia V, Rotilio D, Donati MB, de Gaetano G, Iacoviello L. Modulation of haemostatic function and prevention of experimental thrombosis by red wine in rats: a role for increased nitric oxide production. Br J Pharmacol. 1999; 127: 747755.[Medline] [Order article via Infotrieve]
8.
Fitzpatrick DF, Hirschfield SL, Coffey RG. Endothelium-dependent vasorelaxing activity of wine and other grape products. Am J Physiol. 1993; 265: H774H778.
9. Fitzpatrick DF, Hirschfield SL, Ricci T, Jansen P, Coffey RG. Endothelium-dependent vasorelaxation caused by various plant extracts. J Cardiovasc Pharmacol. 1995; 26: 9095.[Medline] [Order article via Infotrieve]
10.
Cannon RO. Role of nitric oxide in cardiovascular disease: focus on the endothelium. Clin Chem. 1998; 44: 18091819.
11. Andriambeloson E, Kleyschov AL, Muller B, Beretz A, Stoclet JC, Andriantsitohaina R. Nitric oxide production and endothelium-dependent vasorelaxation induced by wine polyphenols in rat aorta. Br J Pharmacol. 1997; 120: 10531058.[Medline] [Order article via Infotrieve]
12. Andriambeloson E, Stoclet JC, Andriantsitohaina R. Mechanism of endothelial nitric oxide-dependent vasorelaxation induced by wine polyphenols in rat thoracic aorta. J Cardiovasc Pharmacol. 1999; 33: 248254.[Medline] [Order article via Infotrieve]
13. Mizutani K, Ikeda K, Kawai Y, Yamori Y. Extract of wine phenolics improves aortic biomechanical properties in stroke-prone spontaneously hypertensive rats (SHRSP). J Nutr Sci Vitaminol (Tokyo). 1999; 45: 95106.[Medline] [Order article via Infotrieve]
14. Duthie GG, Pedersen MW, Gardner PT, Morrice PC, Jenkinson AM, McPhail DB, Steel GM. The effect of whisky and wine consumption on total phenol content and antioxidant capacity of plasma from healthy volunteers. Eur J Clin Nutr. 1998; 52: 733736.[Medline] [Order article via Infotrieve]
15.
Andriambeloson E, Magnier C, Haan-Archipoff G, Lobstein A, Anton R, Beretz A, Stoclet JC, Andriantsitohaina R. Natural dietary polyphenolic compounds cause endothelium-dependent vasorelaxation in rat thoracic aorta. J Nutr. 1998; 128: 23242333.
16.
Adams JD Jr, Lauterburg BH, Mitchell JR. Plasma glutathione and glutathione disulfide in the rat: regulation and response to oxidative stress. J Pharmacol Exp Ther. 1983; 227: 749754.
17. Asensi M, Sastre J, Pallardo FV, Garcia de la Asuncion J, Estrela JM, Vina J. A high-performance liquid chromatography method for measurement of oxidized glutathione in biological samples. Anal Biochem. 1994; 217: 323328.[Medline] [Order article via Infotrieve]
18. Laight DW, Kaw AV, Carrier MJ, Anggard EE. Interaction between superoxide anion and nitric oxide in the regulation of vascular endothelial function. Br J Pharmacol. 1998; 124: 238244.[Medline] [Order article via Infotrieve]
19. Andriambeloson E, Duarte J, Kleschyov A, Stoclet JC, Andriantsitohaina R. Mechanism of nitric oxide production by wine polyphenols in bovine aortic endothelial cells. J Vasc Res. 1997; 34 (suppl I): 5.Abstract.
20.
Dreher D, Jornot L, Junod AF. Effects of hypoxanthine-xanthine oxidase on Ca2+ stores and protein synthesis in human endothelial cells. Circ Res. 1995; 76: 388395.
21.
Hu Q, Corda S, Zweier JL, Capogrossi MC, Ziegelstein RC. Hydrogen peroxide induces intracellular calcium oscillations in human aortic endothelial cells. Circulation. 1998; 97: 268275.
22. Graier WF, Simecek S, Kukovetz WR, Kostner GM. High D-glucose-induced changes in endothelial Ca2+/EDRF signaling are due to generation of superoxide anions. Diabetes. 1996; 45: 13861395.[Abstract]
This article has been cited by other articles:
![]() |
C. Baron-Menguy, A. Bocquet, A.-L. Guihot, D. Chappard, M.-J. Amiot, R. Andriantsitohaina, L. Loufrani, and D. Henrion Effects of red wine polyphenols on postischemic neovascularization model in rats: low doses are proangiogenic, high doses anti-angiogenic FASEB J, November 1, 2007; 21(13): 3511 - 3521. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. E. Mann, D. J. Rowlands, F. Y.L. Li, P. de Winter, and R. C.M. Siow Activation of endothelial nitric oxide synthase by dietary isoflavones: Role of NO in Nrf2-mediated antioxidant gene expression Cardiovasc Res, July 15, 2007; 75(2): 261 - 274. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. W. Erdman Jr., D. Balentine, L. Arab, G. Beecher, J. T. Dwyer, J. Folts, J. Harnly, P. Hollman, C. L. Keen, G. Mazza, et al. Flavonoids and Heart Health: Proceedings of the ILSI North America Flavonoids Workshop, May 31-June 1, 2005, Washington, DC J. Nutr., March 1, 2007; 137(3): 718S - 737S. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Diebolt, L. Germain, F. A. Auger, and R. Andriantsitohaina Mechanism of potentiation by polyphenols of contraction in human vein-engineered media Am J Physiol Heart Circ Physiol, June 1, 2005; 288(6): H2918 - H2924. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Fusi, G. Sgaragli, and S. Saponara Mechanism of Myricetin Stimulation of Vascular L-type Ca2+ Current J. Pharmacol. Exp. Ther., May 1, 2005; 313(2): 790 - 797. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. E. Szmitko and S. Verma Antiatherogenic potential of red wine: clinician update Am J Physiol Heart Circ Physiol, May 1, 2005; 288(5): H2023 - H2030. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. R. Zilkens, V. Burke, J. M. Hodgson, A. Barden, L. J. Beilin, and I. B. Puddey Red Wine and Beer Elevate Blood Pressure in Normotensive Men Hypertension, May 1, 2005; 45(5): 874 - 879. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Dell'Agli, A. Busciala, and E. Bosisio Vascular effects of wine polyphenols Cardiovasc Res, September 1, 2004; 63(4): 593 - 602. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Tawakol, T. Omland, and M. A. Creager Direct effect of ethanol on human vascular function Am J Physiol Heart Circ Physiol, June 1, 2004; 286(6): H2468 - H2473. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Ralay Ranaivo, O. Rakotoarison, A. Tesse, C. Schott, A. Randriantsoa, A. Lobstein, and R. Andriantsitohaina Cedrelopsis grevei induced hypotension and improved endothelial vasodilatation through an increase of Cu/Zn SOD protein expression Am J Physiol Heart Circ Physiol, February 1, 2004; 286(2): H775 - H781. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Taubert, R. Berkels, R. Roesen, and W. Klaus Chocolate and Blood Pressure in Elderly Individuals With Isolated Systolic Hypertension JAMA, August 27, 2003; 290(8): 1029 - 1030. [Full Text] [PDF] |
||||
![]() |
G. I. Togna, A. R. Togna, M. Franconi, C. Marra, and M. Guiso Olive Oil Isochromans Inhibit Human Platelet Reactivity J. Nutr., August 1, 2003; 133(8): 2532 - 2536. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Bernatova, O. Pechanova, P. Babal, S. Kysela, S. Stvrtina, and R. Andriantsitohaina Wine polyphenols improve cardiovascular remodeling and vascular function in NO-deficient hypertension Am J Physiol Heart Circ Physiol, March 1, 2002; 282(3): H942 - H948. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2001 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |